H.C. Wainwright has started coverage on Innoviva (INVA, Financial), giving it a "Buy" rating along with a price target of $40. The firm highlights Innoviva's diverse portfolio that includes various commercial offerings. A key strength noted is the company's stable revenue from its well-established royalty streams tied to major respiratory disease franchises.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Innoviva Inc (INVA, Financial) is $40.50 with a high estimate of $55.00 and a low estimate of $26.00. The average target implies an upside of 115.77% from the current price of $18.77. More detailed estimate data can be found on the Innoviva Inc (INVA) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Innoviva Inc's (INVA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Innoviva Inc (INVA, Financial) in one year is $23.57, suggesting a upside of 25.57% from the current price of $18.77. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Innoviva Inc (INVA) Summary page.
